Clinical Trials Browser

Uterine Cervical Neoplasms, Condylomata Acuminata

NCT03493542 2024-12-31

V501-213

Phase 3 Completed

766 enrolled 38 charts

Gynecologic

Uterine Cervical Dysplasia

NCT06465914 2024-12-12

A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males

Phase 3 Active not recruiting

9,000 enrolled

GastrointestinalGenitourinary

Anus Neoplasms, Condylomata Acuminata, Penile Neoplasms

NCT04422366 2024-06-07

Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Phase 3 Recruiting

8,000 enrolled

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms

NCT05435209 2023-11-29

Effectiveness of the Q-HPV Vaccine 9-years Post Vaccination Among HIV Positive Adolescents

Phase 4 Completed

158 enrolled

Papillomavirus Infections

NCT05584332 2023-07-21

A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females

Phase 3 Terminated

3,131 enrolled

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata

NCT05149248 2021-12-08

CONDESA

Phase 2/3 Completed

6,000 enrolled

Gynecologic

Uterine Cervical Neoplasms, Neoplasms

NCT01245764 2018-11-14

GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)

Phase 3 Completed

250 enrolled 20 charts

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT00090285 2018-08-23

V501-020

Phase 3 Completed

4,065 enrolled 27 charts

Condylomata Acuminata

NCT00411749 2017-04-21

V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)

Phase 2 Completed

107 enrolled 12 charts

Papillomavirus Infections

NCT00496626 2017-04-17

An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects (V501-030)(COMPLETED)

Phase 3 Completed

600 enrolled 12 charts

Papillomavirus Infections

NCT00524745 2017-04-14

Immunogenicity and Reactogenicity of Alternative Schedules of Gardasil

Phase NA Completed

903 enrolled 10 charts

Gynecologic

Uterine Cervical Neoplasms

NCT00092482 2017-03-22

Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)

Phase 3 Completed

3,882 enrolled

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata

NCT00517309 2017-03-22

FUTURE

Phase 3 Completed

1,877 enrolled

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata

NCT00551187 2015-06-08

A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)

Phase 2 Completed

620 enrolled

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT00092495 2015-01-13

Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016)

Phase 3 Completed

3,055 enrolled 25 charts

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata

Clinical Trials

FUTURE II

V501-213

A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males

Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Effectiveness of the Q-HPV Vaccine 9-years Post Vaccination Among HIV Positive Adolescents

A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females

CONDESA

GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)

V501-020

V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)

An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects (V501-030)(COMPLETED)

Immunogenicity and Reactogenicity of Alternative Schedules of Gardasil

Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)

FUTURE

A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)

Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016)